SCHEMBL14309381

SCHEMBL14309381

CN(C)c1cccc(F)c1CN1C[C@H]2N(C(=O)CN2N(C)C(=O)NCc2ccccc2)[C@@H](c2ccccc2)C1=O

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CLPP Q16740 8/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CYP3A4 P08684 3/20 0.32
▸ CTNNB1 P35222 2/20 0.32
▸ TCF7 P36402 2/20 0.32
▸ BCL9 O00512 1/20 0.32
▸ TCF4 P15884 1/20 0.32
▸ CREBBP Q92793 1/20 0.32
▸ CACNA1G O43497 2/20 0.32
▸ CACNA1H O95180 2/20 0.32
▸ CACNA1I Q9P0X4 2/20 0.32
▸ EED O75530 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ SIRT5 Q9NXA8 1/20 0.31
▸ MAOA P21397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14505286 0.94 CLPP (0.36) CLPPL3MBTL1MEN1KMT2ASMN1; SMN2
SCHEMBL14504313 0.90 CLPP (0.33) CLPPL3MBTL1MEN1KMT2ASMN1; SMN2
SCHEMBL14309904 0.89 CLPP (0.45) CLPPCYP3A4CTNNB1TCF7BCL9
SCHEMBL14309899 0.89 CYP3A4 (0.35) CYP3A4
SCHEMBL17572699 0.88 CLPP (0.39) CLPPKMT2ACYP3A4CTNNB1TCF7
SCHEMBL13773713 0.88 CLPP (0.41) CLPPCYP3A4CTNNB1TCF7BCL9
SCHEMBL14319224 0.88 CLPP (0.36) CLPPCYP3A4CTNNB1TCF7BCL9
SCHEMBL14309433 0.87 CACNA1G (0.41) CLPPMEN1KMT2ASMN1; SMN2CACNA1G
SCHEMBL14309913 0.86 CTNNB1 (0.48) CLPPCYP3A4CTNNB1TCF7BCL9
SCHEMBL14308200 0.86 KMT2A (0.39) CLPPL3MBTL1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080009500-A1 Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders INSTITUTE FOR CHEMICAL GENOMICS 2008-01-10 — — US disclosed
US-20070129353-A1 Alpha-helix mimetics and method relating to the treatment of cancer stem cells INSTITUTE FOR CHEMICAL GENOMICS 2007-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009500-A1 Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders COL1A1, COL2A1, PLOD3 CLPP 2188/4885L3MBTL1 1275/4885MEN1 2759/4885
US-20070129353-A1 Alpha-helix mimetics and method relating to the treatment of cancer stem cells MCL1, HNF4A, THPO CLPP 2482/4885L3MBTL1 1321/4885MEN1 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback